z-logo
Premium
Hormone receptor‐negative, thyroid transcription factor 1‐positive uterine and ovarian adenocarcinomas: report of a series of mesonephric‐like adenocarcinomas
Author(s) -
McFarland Marie,
Quick Charles M,
McCluggage W Glenn
Publication year - 2016
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12895
Subject(s) - mesonephric duct , biology , pathology , thyroid transcription factor 1 , calretinin , ovary , cytokeratin , nuclear atypia , adenocarcinoma , immunohistochemistry , endocrinology , medicine , cancer , kidney , genetics
Aims To report a series of uterine corpus ( n = 7) and ovarian ( n = 5) neoplasms which we believe probably represent mesonephric adenocarcinomas based on their characteristic morphology and immunophenotype. Methods and results All neoplasms exhibited a relatively constant and characteristic morphological appearance with an admixture of architectural patterns with small glands or tubules, some containing luminal eosinophilic colloid‐like material, typically predominating. Solid and papillary architectures were also often present. The nuclear features were characteristic with atypical angulated clear vesicular nuclei which often exhibited overlapping. All the tumours were ‘flat’ negative with oestrogen receptor and progesterone receptor and all except one exhibited nuclear staining with thyroid transcription factor 1 ( TTF 1), which was often diffuse. All tumours exhibited wild‐type staining with p53. CD 10, calretinin and GATA binding protein 3 ( GATA 3) were positive in a variable proportion of the neoplasms. Conclusions We believe these neoplasms to represent mesonephric adenocarcinomas which have only rarely been reported to arise in the uterine corpus and never in the ovary. We recommend they be termed mesonephric‐like adenocarcinomas until their histogenesis is firmly established.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here